Cefixime

From Wikipedia, the free encyclopedia

Cefixime
Systematic (IUPAC) name
(6R,7R)-7-{[2-(2-amino-1,3-thiazol-4-yl)-2-(carboxy
methoxyimino)acetyl]amino}-3-ethenyl-8-oxo-5-thia-
1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Identifiers
CAS number 79350-37-1
ATC code J01DD08
PubChem 54362
DrugBank APRD00583
Chemical data
Formula C16H15N5O7S2 
Mol. mass 453.452 g/mol
Pharmacokinetic data
Bioavailability 40% to 50%
Protein binding Approximately 60%
Metabolism  ?
Half life Variable
Average 3 to 4 hours
Excretion Renal and biliary
Therapeutic considerations
Pregnancy cat.

B

Legal status
Routes Oral

Cefixime is an oral third generation cephalosporin antibiotic. It was sold under the trade name Suprax in the USA, until 2003 when it was taken off the market by drug manufacturer Wyeth after its patent expired. The oral suspension form of "Suprax" was re-launched by Lupin in the USA. Cefixime is still available in Canada. It is used to treat gonorrhea[1], tonsilitis[2], and pharyngitis[2].

[edit] References

  1. ^ McMillan A, Young H. (2007). "The treatment of pharyngeal gonorrhoea with a single oral dose of cefixime.". Int J STD AIDS 18 (4): 253-4. doi:10.1258/095646207780658971. PMID 17509176. 
  2. ^ a b Adam D, Hostalek U, Tröster K. (1995). "5-day cefixime therapy for bacterial pharyngitis and/or tonsillitis: comparison with 10-day penicillin V therapy.". Infection 23 (Suppl 2): S83-6. doi:10.1007/BF01742990. PMID 8537138. 

[edit] External links